print_label | resize_label

A TREATMENT FOR ADULTS WITH TYPE 2 DIABETES MELLITUS, IN ADDITION TO DIET AND EXERCISEProven EfficacyCombination therapy has demonstrated reduced A1C levels for type 2 diabetes patients

XIGDUO XR provides an effective treatment option for patients when both dapagliflozin and metformin are appropriate in addition to diet and exercise.1

Use these clinical studies to get a better understanding of how combination treatment can affect the A1C levels of type 2 diabetes mellitus patients.

VIEW KEY CLINICAL DATA

Dapagliflozin 10 mg + Metformin XR vs Metformin XR Alone

Dapagliflozin 10 mg in combination with metformin XR in treatment-naive adults with type 2 diabetes mellitus who had inadequate glycemic control

Dapagliflozin 5 mg + Metformin XR vs Metformin XR Alone

Dapagliflozin 5 mg in combination with metformin XR in treatment-naive adults with type 2 diabetes mellitus who had inadequate glycemic control

Dapagliflozin as Add-On Therapy to Metformin

Dapagliflozin 10 mg and 5 mg in adults with type 2 diabetes mellitus who had inadequate glycemic control with metformin

Dapagliflozin + Metformin vs Glipizide + Metformin

Dapagliflozin as add-on to metformin in adults with type 2 diabetes mellitus vs glipizide as add-on to metformin

There have been no clinical efficacy studies conducted with XIGDUO XR. Relative bioavailability studies between XIGDUO XR and coadministered dapagliflozin and metformin hydrochloride immediate-release (IR) tablets have not been conducted. Bioequivalence of XIGDUO XR to dapagliflozin and metformin XR coadministered as individual tablets was demonstrated in healthy subjects.